Article info

Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry
Free

Authors

  1. Correspondence to Dr Jeffrey A Sparks, Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA; jsparks{at}bwh.harvard.edu; Dr Zachary S Wallace; zswallace{at}mgh.harvard.edu
View Full Text

Citation

Sparks JA, Wallace ZS, Seet AM COVID-19 Global Rheumatology Alliance, et al
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Publication history

  • Received March 22, 2021
  • Accepted May 17, 2021
  • First published May 28, 2021.
Online issue publication 
August 12, 2021

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.